Embecta (EMBC) Competitors $10.32 +0.07 (+0.68%) Closing price 03:35 PM EasternExtended Trading$10.32 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EMBC vs. WRBY, NVCR, LMAT, EYE, ENOV, CNMD, TNDM, SSII, CDRE, and AORTShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), SS Innovations International (SSII), Cadre (CDRE), and Artivion (AORT). These companies are all part of the "medical equipment" industry. Embecta vs. Its Competitors Warby Parker NovoCure LeMaitre Vascular National Vision Enovis CONMED Tandem Diabetes Care SS Innovations International Cadre Artivion Embecta (NASDAQ:EMBC) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment. Is EMBC or WRBY more profitable? Embecta has a net margin of 4.89% compared to Warby Parker's net margin of -1.79%. Warby Parker's return on equity of -2.48% beat Embecta's return on equity.Company Net Margins Return on Equity Return on Assets Embecta4.89% -19.67% 12.27% Warby Parker -1.79%-2.48%-1.29% Does the media prefer EMBC or WRBY? In the previous week, Warby Parker had 3 more articles in the media than Embecta. MarketBeat recorded 5 mentions for Warby Parker and 2 mentions for Embecta. Warby Parker's average media sentiment score of 1.01 beat Embecta's score of 0.08 indicating that Warby Parker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Warby Parker 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, EMBC or WRBY? Embecta has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Warby Parker has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Which has preferable earnings and valuation, EMBC or WRBY? Embecta has higher revenue and earnings than Warby Parker. Warby Parker is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmbecta$1.12B0.54$78.30M$0.9011.47Warby Parker$795.09M2.92-$20.39M-$0.12-185.42 Do institutionals and insiders believe in EMBC or WRBY? 93.8% of Embecta shares are owned by institutional investors. Comparatively, 93.2% of Warby Parker shares are owned by institutional investors. 0.4% of Embecta shares are owned by insiders. Comparatively, 18.2% of Warby Parker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate EMBC or WRBY? Embecta presently has a consensus target price of $19.33, indicating a potential upside of 87.34%. Warby Parker has a consensus target price of $22.88, indicating a potential upside of 2.81%. Given Embecta's higher possible upside, equities research analysts plainly believe Embecta is more favorable than Warby Parker.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Warby Parker 0 Sell rating(s) 7 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.61 SummaryEmbecta and Warby Parker tied by winning 8 of the 16 factors compared between the two stocks. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$599.04M$7.29B$5.54B$8.95BDividend Yield5.85%2.78%5.38%4.08%P/E Ratio11.4727.9427.4020.04Price / Sales0.5432.39419.46118.60Price / Cash3.0722.0836.6357.47Price / Book-0.816.698.085.67Net Income$78.30M$233.06M$3.16B$248.47M7 Day Performance11.21%2.20%2.12%2.90%1 Month Performance-2.73%4.93%4.43%5.75%1 Year Performance-14.50%35.84%35.62%21.36% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta4.3449 of 5 stars$10.32+0.7%$19.33+87.3%-13.6%$599.04M$1.12B11.472,100Negative NewsWRBYWarby Parker2.1924 of 5 stars$22.02+1.3%$22.88+3.9%+37.0%$2.27B$771.32M0.003,780Positive NewsNVCRNovoCure3.6962 of 5 stars$16.61-0.5%$32.83+97.7%+6.4%$1.86B$605.22M0.001,488LMATLeMaitre Vascular2.5822 of 5 stars$83.38+2.0%$97.83+17.3%+3.3%$1.85B$219.86M42.11490EYENational Vision2.6309 of 5 stars$22.69-0.8%$18.67-17.7%+93.6%$1.81B$1.82B63.5613,411ENOVEnovis4.0598 of 5 stars$30.01-0.3%$58.00+93.3%-25.2%$1.72B$2.11B9.597,367CNMDCONMED4.7232 of 5 stars$51.72-0.9%$62.20+20.3%-19.1%$1.61B$1.31B12.083,900News CoverageTNDMTandem Diabetes Care4.3051 of 5 stars$20.22flat$33.43+65.3%-56.4%$1.35B$940.20M-7.272,650Positive NewsSSIISS Innovations InternationalN/A$5.65-18.4%N/AN/A$1.34B$20.65M0.004News CoverageCDRECadre3.6823 of 5 stars$32.76-0.3%$37.50+14.5%-5.7%$1.34B$567.56M34.602,284AORTArtivion2.539 of 5 stars$30.84+1.9%$32.00+3.8%+20.6%$1.29B$388.54M121.001,600 Related Companies and Tools Related Companies WRBY Alternatives NVCR Alternatives LMAT Alternatives EYE Alternatives ENOV Alternatives CNMD Alternatives TNDM Alternatives SSII Alternatives CDRE Alternatives AORT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EMBC) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
